Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect is a papulopustular acneiform rash.
- Ref: Oncoimmunology. 2020 Nov 29;9(1):1848058.
- Année de publication : 2020
- Auteurs : Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M, Frouin E, Azzopardi N, Chevrier J, Serres L, Godet J, Levillain P, Paintaud G, Ferru A, Rouleau L, Delwail A, Silvain C, Tasu JP, Morel F, Ragot S, Lecron JC.
- Réseaux : Réseaux: « Immunothérapies »